Page 4 - Riccardo Perfetti News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Riccardo perfetti. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Riccardo Perfetti Today - Breaking & Trending Today

Applied Therapeutics stock falters on heart disease trial failure

Applied Therapeutics stock falters on heart disease trial failure
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Riccardo Perfetti , Applied Therapeutics ,

Caficrestat May Prevent Worsening of Diabetic Cardiomyopathy

Caficrestat, an oral aldose reductase inhibitor, stabilized cardiac functional capacity in patients with diabetic cardiomyopathy. ....

Riccardo Perfetti , Chief Medical Officer ,

Applied Therapeutics (APLT) Reports Topline Results from the ARISE-HF Phase 3 Study of AT-001

Applied Therapeutics (APLT) Reports Topline Results from the ARISE-HF Phase 3 Study of AT-001
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

James Januzzi , Riccardo Perfetti , Therapeutics Inc , Drug Administration , European Medicines Agency , Applied Therapeutics , Diabetic Cardiomyopathy , Diabetic Peripheral Neuropathy , Chief Medical Officer , Hutton Family Professor , Massachusetts General , New Drug Application , Marketing Authorization Application ,

Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

James Januzzi , Maeve Conneighton , Riccardo Perfetti , Advanz Pharma , Therapeutics Inc , Drug Administration , European Medicines Agency , Exchange Commission , Therapeutics Announces Topline Results , Diabetic Cardiomyopathy , Diabetic Peripheral Neuropathy , Chief Medical Officer , Hutton Family Professor , Massachusetts General , New Drug Application , Marketing Authorization Application , Aldose Reductase , Aldose Reductase Inhibitor , Private Securities Litigation Reform Act ,

Applied Therapeutics Reports Third Quarter 2023 Financial Results

Regulatory submissions on track for govorestat (AT-007) for the treatment of Classic Galactosemia to US FDA and EMA in 4Q 2023Two Upcoming Phase 3. ....

United States , Shoshana Shendelman , Gregory Lewis , Maeve Conneighton , Riccardo Perfetti , Advanz Pharma , James Januzzi , Cardiopulmonary Exercise Testing Laboratory , European Association For The Study Of Diabetes , European Medicines Agency , Drug Administration , Expert Forum On Diabetic Cardiomyopathy , Harvard Medical School , Exchange Commission , Marilyn Barry Fellowship In Cardiology Research , Therapeutics Inc , Classic Galactosemia , Upcoming Phase , Diabetic Cardiomyopathy , Sorbitol Dehydrogenase , Chief Executive Officer , Fourth Quarter , New Drug Application , United States Food , Marketing Authorization Application , Expert Forum ,